SCHEMBL3787774

SCHEMBL3787774

CC(C)(C)C1CN(c2cnc(C#N)cn2)CCN1C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 3/20 0.49
PANK3 Q9H999 1/20 0.43
RIPK1 Q13546 1/20 0.40
PARP1 P09874 2/20 0.39
PARP2 Q9UGN5 1/20 0.39
PIK3CD O00329 10/20 0.39
PIK3R1 P27986 2/20 0.39
JAK3 P52333 2/20 0.39
PIK3C2B O00750 1/20 0.39
AURKA O14965 1/20 0.39
MAP4K4 O95819 1/20 0.39
YES1 P07947 1/20 0.39
HCK P08631 1/20 0.39
FGR P09769 1/20 0.39
EPHA1 P21709 1/20 0.39
GRK4 P32298 1/20 0.39
KDR P35968 1/20 0.39
PIK3CG P48736 1/20 0.39
GSK3A P49840 1/20 0.39
GSK3B P49841 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21981500 0.84 PANK3 (0.41) CHRM4PANK3GRM1
SCHEMBL3554487 0.83 CHRM4 (0.51) CHRM4PANK3PARP1PARP2
SCHEMBL3790060 0.82 GRM1 (0.39) CHRM4GRM1
SCHEMBL25207018 0.81 PANK3 (0.51) CHRM4PANK3
SCHEMBL25264632 0.79 CHRM4 (0.48) CHRM4PARP1
SCHEMBL22638185 0.77 ME2 (0.51) MAPKAPK3GRM1
SCHEMBL19748680 0.77 PANK3 (0.57) CHRM4PANK3RIPK1PARP1PARP2
SCHEMBL23561132 0.76 MAP4K4 (0.52) CHRM4PIK3CDPIK3R1JAK3PIK3C2B
SCHEMBL23560717 0.76 MAP4K4 (0.52) CHRM4PIK3CDPIK3R1JAK3PIK3C2B
SCHEMBL16496558 0.76 GRM1 (0.34) CHRM4GRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118055933-A Selective PARP1 inhibitors and uses thereof 成都百裕制药股份有限公司 2024-05-17 CN disclosed
WO-2023088408-A1 SELECTIVE PARP1 INHIBITOR AND APPLICATION THEREOF 成都百裕制药股份有限公司 2023-05-25 WO disclosed
EP-2398796-A1 HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE Merck Canada Inc. (CA) 2011-12-28 EP disclosed
US-20110301143-A1 HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK CANADA INC. (CA) 2011-12-08 US disclosed
WO-2010094126-A1 HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK FROSST CANADA LTD. (CA) 2010-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301143-A1 HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE SCD, SCD5, COASY CHRM4 3109/4885PANK3 1737/4885RIPK1 2076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.